AbD Serotec will use proprietary technology to generate antibodies against
novel research targets provided by Sigma-Aldrich
MUNICH, Germany and ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ -- Sigma-Aldrich(TM) (Nasdaq: SIAL) and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) today announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich. HuCAL GOLD is the most recent and most powerful phage-display library developed for the in vitro generation of highly specific and fully human antibodies. The large diversity of the library guarantees fast and successful generation of high-quality antibodies to targets that have previously been difficult to probe with standard antibody-generation technologies. Sigma-Aldrich will offer the HuCAL-based recombinant research antibodies for use in research applications through its powerful and unique online sales platforms Antibody Explorer(TM) (http://www.sigma-aldrich.com/antibodies) and Your Favorite Gene Search(TM) (http://www.sigma-aldrich.com/yfg).
"We are very excited about the potential of this partnership," said Dr.
David Smoller, president of Sigma-Aldrich's Research Biotech business unit.
"HuCAL-based recombinant antibody technology will allow researchers access
to antibody content not available through standard antibo
Copyright©2008 PR Newswire.
All rights reserved